Biofrontera

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biofrontera reports Q1 recovery post cyberattack, eyes product expansion

Biofrontera Inc. navigated challenges in Q1 2024, with a cyberattack impacting revenues, but recovery and growth were evident by April 30, 2024.
The company's strategic strengths lie in cost reduction through renegotiations, successful fundraising efforts, and advancements in clinical trials and product development.
Opportunities abound for Biofrontera with upcoming product launches, FDA approvals, and a focus on operational efficiency and financial management to drive future profitability.
Addressing financial challenges and leveraging opportunities will be key for Biofrontera to sustain growth, enhance market position, and deliver value to stakeholders in the coming quarters.

Biofrontera reports robust Q2 sales growth and cost efficiencies

Biofrontera delivered strong sales growth and cost management in Q2 2024, improving financial performance.
While challenges like net losses persist, opportunities exist to leverage momentum for sustained growth.
The company's focus on operational efficiency and revenue expansion sets the stage for future success and value creation.

Biofrontera reports steady Q3 growth amidst operational challenges and opportunities

Biofrontera Inc. showed resilience with revenue growth despite challenges like delayed deliveries.
Strategic strengths include FDA approvals, positive trial results, and focus on operational efficiency.
Challenges in high operating expenses and negative EBITDA highlight areas for improvement.
Opportunities lie in market expansion, clinical trial progress, and strategic financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOBURN, MA / ACCESSWIRE / June 1, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces it has engaged a contract manufacturer to develop a new, low-cost portable photodynamic therapy (PDT) lamp for use with Ameluz® (Ameluz®-PDT). Prior to this engagement, Biofrontera acquired one issued U.S. patent and all rights from one of two inventors on another issued U.S. patent related to a portable red-light lamp for use in PDT.

Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDT

WOBURN, MA / ACCESSWIRE / May 30, 2023 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as Chief Executive Officer. Mr. Luebbert is a founder of the Company and currently serves as Executive Chairman.

Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer

Novel Protocol is Expected to be Less Painful with Efficacy Similar to Conventional PDT WOBURN, MA / ACCESSWIRE / May 15, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that the U.S. Patent and Trademark Office (USPTO) has granted a new patent to Biofrontera Bioscience GmbH related to a photodynamic therapy (PDT) protocol that is expected to be less painful but similarly effective to conventional PDT. This new patent is exclusively licensed to Biofrontera Inc. and expires in April 2039, including a patent term adjustment (PTA) approved by the USPTO.

Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects

Biofrontera Inc. (NASDAQ:BFRI ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Tirth Patel - Investor Relations Hermann Luebbert - Executive Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Welcome to the Biofrontera Inc. First Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded.

Biofrontera Inc. (BFRI) Q1 2023 Earnings Call Transcript

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago.

Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue Estimates

Conference call begins at 8:30 a.m. Eastern time today WOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update

Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial Goals WOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities.

Biofrontera Inc. Announces Resignation of CEO

WOBURN, MA / ACCESSWIRE / May 11, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it has entered into a $6.5 million secured line of credit with MidCap Business Credit, LLC, subject to the borrowing base formula, minimum excess availability and other terms and conditions. "Biofrontera has significant growth potential and this line of credit will enhance our flexibility and liquidity as we scale the business," said Fred Leffler, Chief Financial Officer of Biofrontera Inc. "Specifically, this line of credit will provide readily available and efficient funding to support the working capital changes resulting from our seasonal inventory requirements.

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million

WOBURN, MA / ACCESSWIRE / May 9, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that as part of several Skin Cancer Awareness Month activities taking place throughout the month of May, it is collaborating with The Skin Cancer Foundation to support sun safety awareness and educate the public on pre-cancer and skin cancer prevention, early detection and effective treatment. A key to skin cancer prevention is diagnosing and treating the most common pre-cancer, actinic keratosis (AK).

Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention

WOBURN, MA / ACCESSWIRE / April 28, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 31, 2023 on Friday, May 12, 2023. The results will be released before the market opens and the company will host a conference call at 8:30AM Eastern Time.

Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023

WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the last patient in a Phase I study to evaluate the safety and tolerability of Ameluz® - PDT for treatment of mild to severe actinic keratosis on the face and scalp in the expanded treatment field using 3 tubes of BF-200 ALA 10% gel (Ameluz) has now completed the study. This Phase 1 clinical study is being conducted by Biofrontera Bioscience GmbH, a wholly owned subsidiary of Biofrontera AG.

Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)

WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023. "With this investment in the salesforce, Biofrontera is taking an important step forward in our growth strategy," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "The success of our FDA-approved therapy for actinic keratosis (AK), Ameluz®-PDT, is directly related to our ability to educate dermatologists and patients about AK and the potential health benefits of our therapy.

Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce

Providing live demonstrations of a PDT procedure using the RhodoLED® lamp at booth #2224 WOBURN, MA / ACCESSWIRE / March 17, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology (AAD) Annual Meeting taking place March 17-21, 2023 in New Orleans, LA. "We are excited to once again be part of the year's largest and most prestigious dermatology conference," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "Given the ongoing growth of our Ameluz®-PDT therapy, we welcome the opportunity to continue educating the dermatology community regarding the benefits of photodynamic therapy (PDT) for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions.

Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting

This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release. WOBURN, MA / ACCESSWIRE / March 9, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31, 2022.

CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

Biofrontera, Inc. (NASDAQ:BFRI ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Erica Monaco - CEO, COO, Treasurer & Secretary Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Bruce Jackson - The Benchmark Company Operator Greetings and welcome to the Biofrontera, Inc. Fourth quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode and a question-and-answer session will follow the form of presentation.

Biofrontera, Inc. (BFRI) Q4 2022 Earnings Call Transcript

WOBURN, MA / ACCESSWIRE / March 8, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and twelve months ended December 31, 2022. Highlights Record 2022 annual Ameluz® revenues were 12% higher than previous record in pre-COVID 2019 Grew share in our target market in 2022 by about 12% Total revenues for the fourth quarter of 2022 grew 11% over the fourth quarter of 2021 Total revenues for the year 2022 grew 19% over the year 2021 Average revenue per sales rep grew approximately 20% over 2021 Continued various education initiatives including seminars, medical conferences, prescriber networking and key opinion leader (KOL) engagement Showcased our Ameluz therapy at three conference podiums including Fall Clinical, New Frontiers in Cosmetic Medicine & Medical Dermatology Symposium and Mount Sinai 25th Winter Symposium 4 Poster publications in a peer reviewed dermatology journal, SKIN The Journal of Cutaneous Medicine Education initiatives included a 3-part webinar series for CME credit, a 3-part video series with over 1,200 views and 4-part podcast series with over 1,400 views Ameluz new marketing campaign earned "Relaunch/Revitalization of the Year" and "Professional Website/Online Initiative of the Year" awards Management Commentary "2022 was a pivotal year for Biofrontera highlighted by our record annual Ameluz revenues, up 19% over 2021 and 12% higher than our previous record in pre-COVID 2019," said Erica Monaco, Chief Executive Officer of Biofrontera Inc. "The company continues to make a measurable impact in the AK marketplace in terms of both awareness and market share, and we are pleased that we increased share in our target market by about 12%.

Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results

WOBURN, MA / ACCESSWIRE / March 2, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products will be presenting at the 35th Annual ROTH Conference in Laguna Nigel, CA being held March 12-14, 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial Officer, Fred Leffler will represent the company at the conference.

Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023

WOBURN, MA / ACCESSWIRE / February 22, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2022 on Wednesday, March 8, 2023. The results will be released after the market close and the company will host a conference call at 4:30PM Eastern Time.

Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

WOBURN, MA / ACCESSWIRE / February 15, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Biofrontera, Inc. Chief Executive Officer, Erica Monaco, and Chief Financial Officer, Fred Leffler will represent the company at the conference.

Biofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the first patient has been dosed in a Phase 3 randomized, double-blind, vehicle-controlled, multicenter clinical study to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk. This Phase 3 clinical study is being conducted by Biofrontera Bioscience GmbH, a wholly owned subsidiary of Biofrontera AG.

Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and 12 months ended December 31, 2022. Revenues for the fourth quarter of 2022 are anticipated to be in the range of approximately $10.2 million to $10.4 million, an increase of approximately 12% compared with the fourth quarter of 2021.

Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022

WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022.

Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders

WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in Benchmark's 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.

Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference

Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Wednesday, November 30, 2022, at 12:00 PM EST, Monday, December 5, 2022, at 1:00 PM CST, Friday, December 9, 2022 at 12:00 PM EST and Monday, December 19, 2022 at 1:00 PM PST. Biofrontera Inc. welcomes stakeholders, investors, and other individual followers to register and attend these live events.

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022

WOBURN, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk. The study is being managed by Biofrontera Bioscience GmbH.

News for Biofrontera Stock (BFRI)